Stocks Health care NVO
NYSE · Health careNovo Nordisk A S (NVO)
Novo Nordisk A S reported revenue of DKK 309.1B in fiscal 2025, up 6.4% from a year earlier. Net income was DKK 102.4B, a net margin of 33.1%. Operating cash flow minus capital spending left DKK 59B of free cash flow in fiscal 2025. At December 31, 2025 it held DKK 26.5B in cash against DKK 131B of debt.
What Novo Nordisk A S does
Novo Nordisk is a healthcare company that develops and manufactures prescription pharmaceutical products. It is primarily known for producing insulin and other diabetes medications, as well as obesity treatments, hormone therapies, and treatments for rare blood and endocrine disorders sold to pharmacies and healthcare providers worldwide. Its shares trade on NYSE under the ticker NVO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | DKK 309.1B | DKK 102.4B | DKK 23.03 | DKK 59B |
| 2024 | DKK 290.4B | DKK 101B | DKK 22.63 | DKK 73.8B |
| 2023 | DKK 232.3B | DKK 83.7B | DKK 18.62 | DKK 83.1B |
| 2022 | DKK 177B | DKK 55.5B | DKK 12.22 | DKK 66.7B |
| 2021 | DKK 140.8B | DKK 47.8B | DKK 10.37 | DKK 48.7B |
| 2021 | DKK 126.9B | DKK 42.1B | DKK 9.01 | DKK 46.1B |
Full financial statements: income, balance sheet and cash flow
Where NVO ranks in Health care
Dividends
It paid out DKK 51.8B in cash dividends, 51% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | DKK 51.8B | 51% |
| 2024 | n/a | DKK 44.1B | 44% |
| 2023 | n/a | DKK 31.8B | 38% |
| 2022 | n/a | DKK 25.3B | 46% |
| 2021 | n/a | DKK 21.5B | 45% |
| 2021 | n/a | DKK 20.1B | 48% |
Latest SEC filings
What Novo Nordisk A S has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 21, 2026
- September 17, 2026
- September 15, 2026
- September 9, 2026
- August 31, 2026
- August 24, 2026
- August 18, 2026
- August 10, 2026
- August 10, 2026
- August 4, 2026
Questions about NVO
What does Novo Nordisk A S do?
Novo Nordisk is a healthcare company that develops and manufactures prescription pharmaceutical products. It is primarily known for producing insulin and other diabetes medications, as well as obesity treatments, hormone therapies, and treatments for rare blood and endocrine disorders sold to pharmacies and healthcare providers worldwide. Its shares trade on NYSE under the ticker NVO.
Is Novo Nordisk A S profitable?
Yes. In fiscal 2025 it reported net income of DKK 102.4B on revenue of DKK 309.1B, a net margin of 33.1%.
How much revenue does Novo Nordisk A S make?
In fiscal 2025 Novo Nordisk A S reported revenue of DKK 309.1B. That is 6.4% more than a year earlier.
When did Novo Nordisk A S last report?
Its newest filing of any kind is the foreign issuer update from September 21, 2026.
Similar companies
Compare NVO with
Follow NVO
Get an email when Novo Nordisk A S files with the SEC: results, executive changes, material agreements and annual reports.
Follow NVO: get an email when it filesWhere the numbers come from
Financial figures are the values Novo Nordisk A S tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.